Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone

Launched by SHAARE ZEDEK MEDICAL CENTER · Mar 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called GnRH agonist can improve pregnancy rates for women undergoing frozen embryo transfers (FET) compared to the standard treatment with vaginal progesterone. The goal is to find out if using the GnRH agonist, which is administered as a nasal spray, can help more women achieve a successful pregnancy after FET.

To participate, women must be between the ages of 18 and 40, have a normal menstrual cycle, and be scheduled for a frozen embryo transfer at the Shaare Zedek IVF clinic. The trial will randomly assign participants to one of two groups: one will receive the GnRH agonist nasal spray, while the other will receive vaginal progesterone. Throughout the study, researchers will monitor pregnancy outcomes, including the rates of successful pregnancies and any miscarriages. This trial is important as it could lead to new treatment options that improve the chances of pregnancy and support the overall well-being of women undergoing fertility treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Women treated at the Shaare Zedek IVF clinic scheduled for frozen embryo transfer
• • 2. Normo-ovulatory women
• • 3. Women undergoing frozen embryo transfer in a modified natural cycle
• • 4. BMI 18-35
• • 5. Age 18-40
• Exclusion Criteria:
• • 1. Women undergoing medicated FET cycles
• • 2. BMI \>35 or \<18
• • 3. Women with hydrosalpinx
• • 4. Women with congenital or acquired uterine anomalies (e.g., myomas)
• • 5. Egg donation or surrogacy
• • 6. Women with endometriosis
• • 7. Intolerance to GnRH agonists
• • 8. Nasal congestion or respiratory conditions affecting nasal absorption